Prelude Therapeutics reports Q3 results
Prelude Therapeutics (PRLD) reported Q3 GAAP EPS loss of $0.12, revenue of $5.6M (down 13% Y/Y), and net loss of $12.5M (down 36% Y/Y). R&D expenses fell 32% to $14.8M, while G&A expenses decreased 2% to $5.1M. The company had $142.7M in cash and equivalents, with a runway into Q2 2028.


